| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-12-17 | Imaxio (France) Merial, a Sanofi company (France) | animal health vaccine based on Imaxio’s immune-enhancing IMX313 technology | development |
Veterinary medicine | Development agreement | |
| 2012-12-17 | Phenex Pharmaceuticals (Germany) Janssen Biotech - J&J (USA) | compounds that target the nuclear hormone receptor RORgammaT | rheumatoid arthritis, psoriasis, inflammatory bowel disease | R&D |
Autoimmune diseases - Dermatological diseases - Inflammatory diseases - Rheumatic diseases | R&D agreement |
| 2012-12-17 | MedImmune (USA - global biologics arm of AstraZeneca (UK) - Progenics Pharmaceuticals (USA) | Clostridium difficile late-stage preclinical program | Clostridium difficile infections | licensing |
Infectious diseases | Licensing agreement |
| 2012-12-17 | Evotec (Germany) Janssen Pharmaceuticals - J&J (USA) | NR2B subtype selective NMDA-antagonist portfolio | depression, major depressive disorder (MDD) | licensing |
CNS diseases - Mental diseases | Licensing agreement |
| 2012-12-17 | SpePharm Holding (The Netherlands) Norgine BV (The Netherlands) | joint-venture |
Joint-venture agreement | |||
| 2012-12-16 | Teva Pharmaceuticals (Israel) HANDOK Pharmaceuticals (South Korea) | joint-venture |
Joint-venture agreement | |||
| 2012-12-16 | Roche (Switzerland) ProMining Therapeutics (Israel) | small molecule therapeutics developed on the basis of the CavitIIRx platform | type 2 diabetes | Metabolic diseases | R&D agreement | |
| 2012-12-13 | Eisai (Japan) University College London - UCL (UK) | novel drug targets and new therapeutics | neurological diseases such as Alzheimer's, Parkinson's and other related disorders | R&D |
Neurodegenerative diseases - CNS diseases | R&D agreement |
| 2012-12-11 | Teva Pharmaceutical Industries (Israel) Xenon Pharmaceuticals (USA) | XEN402 | painful disorders, pain | development |
CNS diseases | Development agreement |
| 2012-12-10 | Myriad Genetics (USA) Sanofi (France) Population Health Research Institute (PHRI) (USA) | protein biomarkers | diabetes | R&D |
Metabolic diseases | R&D agreement |
| 2012-12-10 | GSK (UK) Fred Hutchinson Cancer Research Center (USA) | small-molecule-based inhibiting the activity of a protein that is incorrectly expressed by the DUX4 gene | facioscapulohumeral muscular dystrophy (FSHD) | development |
Rare diseases - Neuromuscular diseases | Development agreement |
| 2012-12-07 | GSK (UK) The University of Texas MD Anderson Cancer Center (USA) | therapeutic antibodies which activate OX40 | R&D |
Cancer - Oncology | R&D agreement | |
| 2012-12-07 | Debiopharm Group (Switzerland) Dr Reddy\'s (India) | Pamorelin® LA (triptorelin) | locally advanced or metastatic, hormone-dependent prostate cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2012-12-05 | Genmab (Denmark) Kyowa Hakko Kirin (Japan) | bispecific antibodies using Genmab\'s DuoBody technology | undisclosed | R&D |
undisclosed | R&D agreement |
| 2012-12-05 | Apexigen (USA) Boehringer Ingelheim (Germany) | development and manufacturing services for APX005, a humanized monoclonal antibody targeting CD40 for the treatment of cancers | cancers | manufacturing |
Cancer - Oncology | Production agreement |
| 2012-12-04 | Galena Biopharma (USA) Teva Pharmaceutical (Israel) | NeuVax™ (nelipepimut-S or E75) | breast cancer | commercialisation |
Cancer - Oncology | Commercialisation agreement |
| 2012-12-04 | Alimera Sciences (USA) Quintiles Commercial Europe Ltd (UK) | Iluvien® (190 micrograms fluocinolone acetonide intravitreal implant in applicator) | vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies | promotion - commercialisation - services | Ophtalmological diseases | Commercialisation agreement |
| 2012-12-03 | UCB (Belgium) biOasis Technologies (Canada) | Transcend technology | R&D |
CNS diseases | R&D agreement | |
| 2012-11-30 | Ghent University (Belgium) MDxHealth (Belgium) | NXTGNT - Center in Pharmaco (Epi)genomics | R&D |
Cancer - Oncology | R&D agreement | |
| 2012-11-29 | Medigene (Germany) Nordic Pharma (France - Sweden) | Veregen® ointment (made from the extract of green tea leaves - catechins) | genital warts | commercialisation |
Infectious diseases - Gynecology - Women's health | Commercialisation agreement |
